Daix (France), Long Island City (New York, United States) - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, announced the results of the votes of its Combined Shareholders' Meeting.

The Combined Shareholders' Meeting was held on Thursday May 19, 2022 at 2 p.m. at Hotel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frederic Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.

Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the Combined Shareholders' Meeting.

Contact:

Brunswick

Yannick Tetzlaff

Tristan Roquet Montegon

Aude Lepreux

Media

E: inventiva@brunswickgroup.com

T: +33 1 53 96 83 83

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

(C) 2022 Electronic News Publishing, source ENP Newswire